Cargando…

The influence of chemotherapy on adenosine-producing B cells in patients with head and neck squamous cell carcinoma

INTRODUCTION: Head and neck squamous cell carcinoma (HNSCC) strongly suppresses the immune system, resulting in increased metastasis and recurrent disease. Chemotherapy is part of the multimodal treatment but may further immunosuppression. Recently, we demonstrated that regulatory B cells (Breg), de...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziebart, Andreas, Huber, Ulrich, Jeske, Sandra, Laban, Simon, Doescher, Johannes, Hoffmann, Thomas K., Brunner, Cornelia, Jackson, Edwin K., Schuler, Patrick J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814178/
https://www.ncbi.nlm.nih.gov/pubmed/29464038
http://dx.doi.org/10.18632/oncotarget.23533
_version_ 1783300295355269120
author Ziebart, Andreas
Huber, Ulrich
Jeske, Sandra
Laban, Simon
Doescher, Johannes
Hoffmann, Thomas K.
Brunner, Cornelia
Jackson, Edwin K.
Schuler, Patrick J.
author_facet Ziebart, Andreas
Huber, Ulrich
Jeske, Sandra
Laban, Simon
Doescher, Johannes
Hoffmann, Thomas K.
Brunner, Cornelia
Jackson, Edwin K.
Schuler, Patrick J.
author_sort Ziebart, Andreas
collection PubMed
description INTRODUCTION: Head and neck squamous cell carcinoma (HNSCC) strongly suppresses the immune system, resulting in increased metastasis and recurrent disease. Chemotherapy is part of the multimodal treatment but may further immunosuppression. Recently, we demonstrated that regulatory B cells (Breg), defined as CD19(+)CD39(+)CD73(+) B cells, play a significant role in the production of immunosuppressive, extracellular adenosine (ADO). Here, we tested the influence of chemotherapy on Breg function. RESULTS: In HNSCC patients, Breg were diminished in absolute number and frequency after chemotherapy (paired samples). Chemotherapeutic drugs had variable effects; while platinum-based chemotherapy decreased the expression of CD39, methotrexate led to a functional increase in CD39 expression and increased production of immunosuppressive ADO. These findings were confirmed in a second patient cohort. Surface expression of CD39 correlated strongly with the production of ADO as measured by mass spectrometry. CONCLUSIONS: Platinum-based anti-tumor-therapy reduces the number of adenosine-producing B cells and, consequently, potential immunosuppression within the tumor environment. Breg function in terms of ADO production and their potential capacity to suppress CD4(+) T cells are promoted by methotrexate treatment amplifying anti-inflammatory therapeutic effects. Our results add to the understanding of how chemotherapeutic drugs can influence the human immune system and may therefore help to orchestrate standard oncologic therapy with new immune modulating approaches. METHODS: Mononuclear cells were collected prospectively from HNSCC patients before and after chemotherapy (n = 18), from healthy donors (n = 20), and an additional cohort sampled several months after chemotherapy (n = 14). Frequency, phenotype, and function of Breg were determined by multicolor flow cytometry, ATP luminescence assay as well as mass spectrometry measuring 5′-AMP, ADO, and inosine. Isolated B cells were incubated with chemotherapeutic drugs (cisplatin, methotrexate, paclitaxel, 5-fluorouracil) in vitro for functional studies.
format Online
Article
Text
id pubmed-5814178
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-58141782018-02-20 The influence of chemotherapy on adenosine-producing B cells in patients with head and neck squamous cell carcinoma Ziebart, Andreas Huber, Ulrich Jeske, Sandra Laban, Simon Doescher, Johannes Hoffmann, Thomas K. Brunner, Cornelia Jackson, Edwin K. Schuler, Patrick J. Oncotarget Research Paper INTRODUCTION: Head and neck squamous cell carcinoma (HNSCC) strongly suppresses the immune system, resulting in increased metastasis and recurrent disease. Chemotherapy is part of the multimodal treatment but may further immunosuppression. Recently, we demonstrated that regulatory B cells (Breg), defined as CD19(+)CD39(+)CD73(+) B cells, play a significant role in the production of immunosuppressive, extracellular adenosine (ADO). Here, we tested the influence of chemotherapy on Breg function. RESULTS: In HNSCC patients, Breg were diminished in absolute number and frequency after chemotherapy (paired samples). Chemotherapeutic drugs had variable effects; while platinum-based chemotherapy decreased the expression of CD39, methotrexate led to a functional increase in CD39 expression and increased production of immunosuppressive ADO. These findings were confirmed in a second patient cohort. Surface expression of CD39 correlated strongly with the production of ADO as measured by mass spectrometry. CONCLUSIONS: Platinum-based anti-tumor-therapy reduces the number of adenosine-producing B cells and, consequently, potential immunosuppression within the tumor environment. Breg function in terms of ADO production and their potential capacity to suppress CD4(+) T cells are promoted by methotrexate treatment amplifying anti-inflammatory therapeutic effects. Our results add to the understanding of how chemotherapeutic drugs can influence the human immune system and may therefore help to orchestrate standard oncologic therapy with new immune modulating approaches. METHODS: Mononuclear cells were collected prospectively from HNSCC patients before and after chemotherapy (n = 18), from healthy donors (n = 20), and an additional cohort sampled several months after chemotherapy (n = 14). Frequency, phenotype, and function of Breg were determined by multicolor flow cytometry, ATP luminescence assay as well as mass spectrometry measuring 5′-AMP, ADO, and inosine. Isolated B cells were incubated with chemotherapeutic drugs (cisplatin, methotrexate, paclitaxel, 5-fluorouracil) in vitro for functional studies. Impact Journals LLC 2017-12-20 /pmc/articles/PMC5814178/ /pubmed/29464038 http://dx.doi.org/10.18632/oncotarget.23533 Text en Copyright: © 2018 Ziebart et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Ziebart, Andreas
Huber, Ulrich
Jeske, Sandra
Laban, Simon
Doescher, Johannes
Hoffmann, Thomas K.
Brunner, Cornelia
Jackson, Edwin K.
Schuler, Patrick J.
The influence of chemotherapy on adenosine-producing B cells in patients with head and neck squamous cell carcinoma
title The influence of chemotherapy on adenosine-producing B cells in patients with head and neck squamous cell carcinoma
title_full The influence of chemotherapy on adenosine-producing B cells in patients with head and neck squamous cell carcinoma
title_fullStr The influence of chemotherapy on adenosine-producing B cells in patients with head and neck squamous cell carcinoma
title_full_unstemmed The influence of chemotherapy on adenosine-producing B cells in patients with head and neck squamous cell carcinoma
title_short The influence of chemotherapy on adenosine-producing B cells in patients with head and neck squamous cell carcinoma
title_sort influence of chemotherapy on adenosine-producing b cells in patients with head and neck squamous cell carcinoma
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814178/
https://www.ncbi.nlm.nih.gov/pubmed/29464038
http://dx.doi.org/10.18632/oncotarget.23533
work_keys_str_mv AT ziebartandreas theinfluenceofchemotherapyonadenosineproducingbcellsinpatientswithheadandnecksquamouscellcarcinoma
AT huberulrich theinfluenceofchemotherapyonadenosineproducingbcellsinpatientswithheadandnecksquamouscellcarcinoma
AT jeskesandra theinfluenceofchemotherapyonadenosineproducingbcellsinpatientswithheadandnecksquamouscellcarcinoma
AT labansimon theinfluenceofchemotherapyonadenosineproducingbcellsinpatientswithheadandnecksquamouscellcarcinoma
AT doescherjohannes theinfluenceofchemotherapyonadenosineproducingbcellsinpatientswithheadandnecksquamouscellcarcinoma
AT hoffmannthomask theinfluenceofchemotherapyonadenosineproducingbcellsinpatientswithheadandnecksquamouscellcarcinoma
AT brunnercornelia theinfluenceofchemotherapyonadenosineproducingbcellsinpatientswithheadandnecksquamouscellcarcinoma
AT jacksonedwink theinfluenceofchemotherapyonadenosineproducingbcellsinpatientswithheadandnecksquamouscellcarcinoma
AT schulerpatrickj theinfluenceofchemotherapyonadenosineproducingbcellsinpatientswithheadandnecksquamouscellcarcinoma
AT ziebartandreas influenceofchemotherapyonadenosineproducingbcellsinpatientswithheadandnecksquamouscellcarcinoma
AT huberulrich influenceofchemotherapyonadenosineproducingbcellsinpatientswithheadandnecksquamouscellcarcinoma
AT jeskesandra influenceofchemotherapyonadenosineproducingbcellsinpatientswithheadandnecksquamouscellcarcinoma
AT labansimon influenceofchemotherapyonadenosineproducingbcellsinpatientswithheadandnecksquamouscellcarcinoma
AT doescherjohannes influenceofchemotherapyonadenosineproducingbcellsinpatientswithheadandnecksquamouscellcarcinoma
AT hoffmannthomask influenceofchemotherapyonadenosineproducingbcellsinpatientswithheadandnecksquamouscellcarcinoma
AT brunnercornelia influenceofchemotherapyonadenosineproducingbcellsinpatientswithheadandnecksquamouscellcarcinoma
AT jacksonedwink influenceofchemotherapyonadenosineproducingbcellsinpatientswithheadandnecksquamouscellcarcinoma
AT schulerpatrickj influenceofchemotherapyonadenosineproducingbcellsinpatientswithheadandnecksquamouscellcarcinoma